# Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

> **NCT02723331** · PHASE2 · COMPLETED · sponsor: **Academic Thoracic Oncology Medical Investigators Consortium** · enrollment: 48 (actual)

## Conditions studied

- Pancreatic Cancer
- Pancreatic Adenocarcinoma
- Pancreas Ductal Adenocarcinoma

## Interventions

- **DRUG:** Nab paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02723331
- **Lead sponsor:** Academic Thoracic Oncology Medical Investigators Consortium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-30
- **Primary completion:** 2022-12-08
- **Final completion:** 2022-12-28
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-07-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02723331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02723331, "Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02723331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*